Overview

Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.

Status:
Terminated
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
The primary objective is to test the hypothesis that enoxaparin efficacy is reduced in severe nephrotic syndrome. Another purpose is to compare two dosing regimens.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Military Institute of Medicine, Poland
Treatments:
Enoxaparin